Precision BioSciences Announces Program Updates Across Its Allogeneic CAR T Pipeline
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences announced updates on its allogeneic CAR T pipeline, with improved safety profile for Azer-Cel compared to prior cohorts. No grade 3 or greater allogeneic CAR T related adverse events were observed.
May 31, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precision BioSciences' allogeneic CAR T pipeline update shows improved safety profile for Azer-Cel, with no grade 3 or greater adverse events.
The announcement of an improved safety profile for Azer-Cel in Precision BioSciences' allogeneic CAR T pipeline is a positive development for the company. This may lead to increased investor confidence and a potential short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100